(Q35927586)

11 August 2017

1 reference

title

Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge (English)

1 reference

11 August 2017

Ralph Smalling

1

1 reference

11 August 2017

MaryAnn Foote

2

1 reference

11 August 2017

Graham Molineux

3

1 reference

11 August 2017

Steven J Swanson

4

1 reference

11 August 2017

Steve Elliott

5

1 reference

11 August 2017

publication date

1 January 2004

1 reference

Biotechnology Annual Review

11 August 2017

published in

1 reference

11 August 2017

volume

10

1 reference

11 August 2017

page(s)

237-250

1 reference

Azathioprine as possible explanation of etiology of pure red cell aplasia in myasthenics

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Cyclosporine in the treatment of azathioprine-induced red cell aplasia following renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Azathioprine-associated pure red cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Pure red cell aplasia induced by FK506

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Transient pure red cell aplasia caused by antilymphoblast globulin after cadaveric renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Linezolid-induced pure red blood cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

A case of isoniazid-induced red cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Pure red cell aplasia and hepatitis in a child receiving isoniazid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Isoniazid-induced pure red cell aplasia in two siblings

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Rifampicin-induced pure red cell aplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Adult pure red cell aplasia following topical ocular chloramphenicol

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Interferon-alpha-induced pure red cell aplasia following chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Lamivudine-induced pure red cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Reversible zidovudine-induced pure red-cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Reversible zidovudine-induced pure red cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Cytopenia and fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Valproic acid-induced cytopenias: evidence for a dose-related suppression of hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Pure red-cell aplasia and recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Pure red-cell aplasia due to anti-erythropoietin antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Role of the kidney in erythropoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Presence of plasma erythropoietin in hypoxic rats with or without kidney (s) and/or spleen

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Renal and extrarenal erythropoietin production in anaemic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Erythropoietin messenger RNA levels in developing mice and transfer of 125I-erythropoietin by the placenta

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Erythropoietin gene expression in human, monkey and murine brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Purification of erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Site-specific antibodies to human erythropoietin directed toward the NH2-terminal region

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Isolation and characterization of genomic and cDNA clones of human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Cloning and expression of the human erythropoietin gene

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Monkey erythropoietin gene: cloning, expression and comparison with the human erythropoietin gene

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Enhancement of therapeutic protein in vivo activities through glycoengineering

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Characterization of a monoclonal antibody to human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Pure Red Cell Aplasia: Studies on an IgG Serum Inhibitor Neutralizing Erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Autoantibodies against erythropoietin in a patient with pure red-cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Human immune response to recombinant human proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910008-2

7 January 2021

10.1016/S1387-2656(04)10008-2

Identifiers

DOI

0 references

1 reference